Agomab Therapeutics(AGMB)
Belgium - AntwerpenBiotechnology
Focus: Agomab Therapeutics is a public Belgian biotech company specializing in agonistic monoclonal antibody molecules, currently trading on the public markets with a focused pipeline in immunology and fibrotic disease.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
5+2 this month
Stable — net +2 jobs in 30d
4 added, 2 removed. Backfill posture.
Should You Work at Agomab Therapeutics?
AI assessmentBest suited for early-career scientists or specialists seeking focused platform expertise and upside optionality; avoid if seeking rapid advancement or near-term commercial upside.
Why Work Here
- Early-stage pipeline with lead asset (AGMB-129) in Phase 2 for fibrostenotic Crohn's disease, offering meaningful near-term clinical catalysts and IP building opportunities.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ORG-129
Healthy VolunteersClinical Trials (1)
NCT04933565First in Human Study of ORG-129 in Healthy Volunteers
Phase 1Help build intelligence for Agomab Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.